KLK3 and prostate carcinoma: Here, we evaluate whether baseline plasma cfDNA concentrations and cfDNA fragment size can differentiate among: (1) men with prostate cancer and controls; and (2) clinical characteristics or biochemical recurrence among men with localized disease (i.e., PSA at diagnosis, Gleason, organ confinement, extraprostatic extension, seminal vesicle invasion, lymph node invasion, and RNA gene expression).